DailyIQ
Last updatedUpdating…

EW·Edwards Lifesciences Corporation

$86.45
+1.18 (+1.38%)
High
$86.62
Open
$85.47
Market Cap
49.38B
52W High
$96.29
Low
$84.83
P. Close
$86.45
P/E
49.14
52W Low
$72.40
Fwd P/E
25.25
DailyIQ Est.
$104.46
Inst. Ownership
46.2%
Short Interest
1.65%
Days to Cover
2.5
Technical Score (1D)
36
BEARISH
News Sentiment
55
BULLISH
The 1D score for Edwards Lifesciences Corporation (EW) is 36, with a SELL lean and weakening momentum. The price structure is compressed and neither trend indicators nor sentiment are offering a strong directional read right now. Sentiment at 55 is diverging from the flat technical backdrop - the two are essentially in sync, but both are pointing to indecision rather than conviction. Trying to get ahead of the direction in conditions like this tends to produce more frustration than results. Traders should watch for a breakout from the $83.09 to $90.01 range, treating either extreme as a potential trigger. Patience at this stage typically outperforms forcing a trade. The longer EW sits between $83.09 and $90.01 without resolving, the more energy tends to build for whichever direction eventually wins out. That's not a reason to anticipate the break - it's a reason to have orders ready on both sides so the reaction, whenever it comes, doesn't get missed entirely.
LOW TARGET
$84 -2.8%
1 analysts
MEAN TARGET
$102 +17.9%
24 analysts
HIGH TARGET
$110 +27.2%
17 analysts
PRICE RANGE
$84.00 - $110.00
SB / B / H / S / SS
13/18/9/1/1
DAILYIQ EST.
$104.46 (+20.8%)
Sector
Healthcare
Industry
Medical Devices
Exchange
NYQ
Country
United States
Symbol
EW
Description
Edwards Lifesciences is a global medical technology company specializing in innovative solutions for advanced cardiovascular diseases. The company's core business centers on developing and commercializing transcatheter heart valve technologies, including the Edwards SAPIEN family, which offers minimally invasive aortic valve replacement. Beyond aortic valves, Edwards also provides solutions for mitral and tricuspid valve repair and replacement, utilizing brands like PASCAL PRECISION and Cardioband. Furthermore, the company's portfolio includes surgical structural heart solutions, such as the INSPIRIS and MITRIS RESILIA valves, catering to a broad spectrum of patient needs. Edwards Lifesciences distributes its products through a direct sales force and independent distributors, solidifying its presence in key markets across the United States, Europe, Japan, and internationally.
Bought (1Y)
0 shares
$0
Sold (1Y)
66,601.39 shares
$5.7M
Lippis Daniel J.CVP, TAVR
Option Exercise619 shares2026-10-08
Lippis Daniel J.CVP, TAVR
Sell619 shares2026-10-08
Lippis Daniel J.CVP, TAVR
Option Exercise619 shares2026-10-08
Markowitz WayneCVP, JAPAC
Tax Withholding568 shares2026-09-14
Dahl Andrew M.SVP, Corporate Controller
Tax Withholding253 shares2026-09-13
85/ 100
Bullish
Overall: Bullish
✓Revenue growing year over year
✓Positive net margin
✓Positive operating cash flow
Gross Margin
78.0%
Net Margin
17.7%
Revenue CAGR
9.8%
Current Ratio
3.72x
Debt / Equity
0.06x
Return on Equity
10.4%
Earnings Summary
Edwards Lifesciences is a global medical technology company focused on advanced cardiovascular solutions, primarily transcatheter heart valves such as the SAPIEN family, and expanding into mitral, tricuspid, and pediatric valve therapies. Operating within the medical devices sector, the company serves key markets in the United States, Europe, Japan, and beyond, leveraging a direct sales force and independent distributors. In the most recent quarters, Edwards delivered robust revenue growth, with Q4 2025 revenue of $1.5696 billion slightly above the $1.5661 billion estimate, and Q1 2026 revenue of $1.6486 billion beating the $1.6437 billion estimate; Q2 2026 revenue rose to $1.7410 billion versus a $1.6995 billion estimate, marking a 5.5% YoY increase. EPS trends mirrored revenue, with Q4 2025 EPS of $0.58 falling short of the $0.6903 estimate, while Q1 2026 EPS of $0.78 exceeded the $0.749 estimate and Q2 2026 EPS of $0.78 surpassed the $0.7421 estimate, indicating a pattern of EPS beats in the last three quarters. Historically, the company has shown consistent YoY revenue growth, with a 4.5% increase in Q1 2025 and a 9.3% rise in Q2 2025, and has frequently outperformed analyst expectations on EPS, though occasional misses have occurred. Recent news highlights the FDA approval of the AUTUS Size‑Adjustable Pulmonary Valve on October 1, 2026, expanding Edwards’ pediatric portfolio and potentially driving future revenue streams; the company also scheduled its September 30, 2026 operating results release and an investor event at the TCT symposium, underscoring its commitment to transparency and stakeholder engagement. Key will be how the new AUTUS valve adoption translates into incremental sales and whether the company maintains its EPS beat trend amid rising operating costs.

EPS

EstBeatMiss
$0.55$0.61$0.68$0.74$0.81Q2'25Q3'25Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$0.74 - -
Q2'26$0.74$0.78+5.1%
Q1'26$0.75$0.78+4.1%
Q4'25$0.69$0.58-16.0%
Q3'25$0.59$0.67+12.6%
Q2'25$0.62$0.67+7.6%

Revenue

EstBeatMiss
$1.5B$1.6B$1.6B$1.7B$1.8BQ2'25Q3'25Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$1.7B - -
Q2'26$1.7B$1.7B+2.4%
Q1'26$1.6B$1.6B+0.3%
Q4'25$1.6B$1.6B+0.2%
Q3'25 - $1.6B -
Q2'25 - $1.5B -

Market Data

EW Stock Snapshot

NEUTRAL36/100
$86.45+$1.18 (1.4%)
Market cap
49.38B
P/E ratio
49.1
Day range
$84.83 – $86.62
News sentiment
55/100 · Neutral
Analyst target
$101.96 (+17.9%)
Consensus
Buy · 42 analysts
52-week range+19.4% off low · -10.2% from high
$72.40$96.29
Price $86.45 DailyIQ Est. $104.46

The technical read on EW is balanced, which usually means the market is waiting on a catalyst. Sector peers are worth watching - large caps in Healthcare tend to move together on rotation.

Reverse DCF

What growth is priced into EW?

RICH

At today's price, Edwards Lifesciences Corporation needs to grow free cash flow about 20.2% a year for the next 10 years to justify its valuation at a 8.47% cost of capital. Over its actual history it has compounded free cash flow at 12.3% a year, so the market is asking for 7.9 percentage points above its own delivered rate. On that basis EW looks priced above what its own growth record supports.

Implied FCF growth
20.2%
Historical FCF CAGR
12.3%
Growth gap
+7.9 pts
Verdict
RICH
Discount rate (WACC)
8.47%
Beta
0.65

Behaviour On Record

What EW's own history says about today's numbers

Realized volatility (21d)
24.7% 40th pct
Below its peak
-34.7%
vs 200-day average
+0.2%
Up days (1y)
51%

Edwards Lifesciences Corporation is currently running 24.7% annualised volatility over the last 21 sessions. Measured against EW's own 13 years of daily returns rather than a market-wide average, that is the 40th percentile — close to its own typical level, against a typical reading of 26.9%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.

EW is trading -34.7% below its running peak. Across 12 full years on file, its median worst-drawdown-in-a-year was -18.4%, and the deepest was -46.3% in 2022. The current drawdown is already deeper than this stock's typical annual low point, which puts it in the part of its range where past recoveries began — and where past declines also continued.

Price sits +0.2% from its 200-day moving average. Against every other day in its history, that gap ranks at the 29th percentile — a narrower gap than it typically runs. Over the past year EW closed higher on 51% of sessions, and it is currently 1 session into a falling streak.

On October specifically: over 13 years of records, EW finished the month higher 6 of 13 times, with a median return of -6.4% and an average of -2.6%. Its strongest month historically has been November at +4.7% on average, its weakest October at -2.6%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.

Overnight risk is measurable too: EW has opened more than 2% away from the prior close in 118 of 3,267 sessions (3.6% of the time), with the largest gaps running +11.0% and -13.1%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.

Across the last 3 dated reports on file, EW moved an average of 2.1% in the session after earnings, closing higher 1 of those 3 times, with a median move of -0.3% and a largest of -5.5%.

All figures computed from 3,268 daily closes between 2013-10-15 and 2026-10-13, split-adjusted, recomputed daily. Percentiles are against EW's own 13-year history, not a peer group or index.

Sector Rotation

Is money rotating into or out of EW's sector?

Edwards Lifesciences Corporation sits in the Health Care sector, currently ranked 2nd of 12 GICS sectors by relative-strength rotation score (leading). Within its narrower Medical Devices industry group, EW ranks 3rd of 15 tracked industries, leading.

Sector rank
#2 of 12
Sector state
Leading
Sector rotation score
91
Industry rank
#3 of 15

Options Market

What is the options market pricing for EW?

CallsPuts

For Edwards Lifesciences Corporation's nearest expiry (2026-10-16, 2 days out), open interest is call-heavy, a bullish tilt (put/call ratio of 0.56), with at-the-money implied volatility around 42.9%. The options market is pricing roughly a ±2.7% move by that expiry — a range of about $83.61–$88.23.

Put/call ratio (2026-10-16)
0.56
ATM implied volatility
42.9%
Total open interest
4,705
Expected move by 2026-10-16
±2.7% ($83.61–$88.23)

Analyst Rating Changes

Are analysts turning bullish or bearish on EW?

Barclays most recently initiated coverage on Edwards Lifesciences Corporation to Overweight on Oct 7, 2026 with a price target of $110. Over the last 90 days, coverage has run 1 upgrade against 0 downgrades, a net bullish lean.

Latest action
Barclays — Overweight
90-day upgrades
1
90-day downgrades
0
Net rating momentum
+1
DateFirmActionRatingPrice target
Oct 7, 2026BarclaysInitiatedOverweight$110
Sep 11, 2026BTIGReiteratedBuy$110
Jul 25, 2026Leerink PartnersUpgradeMarket Perform → Outperform$87 → $101
Jul 24, 2026JP MorganMaintainedOverweight$100 → $105
Jul 24, 2026Piper SandlerReiteratedOverweight$100 → $101
Jul 16, 2026Truist SecuritiesMaintainedHold$90 → $95
Jul 15, 2026MizuhoMaintainedOutperform$100 → $105
Jul 13, 2026RBC CapitalMaintainedOutperform$100 → $110
Jul 8, 2026CitigroupMaintainedBuy$101 → $110
Jul 6, 2026Evercore ISI GroupMaintainedOutperform$93 → $100
Jun 30, 2026BTIGMaintainedBuy$100 → $110
Jun 16, 2026RBC CapitalReiteratedOutperform$100

Peers & ETF holders

EW peers & ETF holders

News Sentiment Analysis

Sentiment gathered from recent headlines

55/100
Strong NegativeNeutralStrong Positive
MODERATELY BULLISH

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles
What did this article say?
Edwards Lifesciences (EW) scheduled the release of its September 30, 2026 operating results for after market close on November 4, 2026. The company will host a conference call at 5:00 p.m. ET that day to discuss the results and answer investor questions. The call will be accessible via phone and live streaming on the Edwards Investor Relations website. No guidance or performance updates were provided in the announcement, and the timing aligns with the company’s regular quarterly reporting schedule.
What did this article say?
Barclays analyst Christopher Pasquale began coverage of Edwards Lifesciences (EW) on October 7, assigning an Overweight rating and setting a price target of $110. The move signals a modest bullish stance, suggesting the bank sees potential upside in EW’s business model and market positioning. The rating and target reflect confidence in EW’s growth prospects relative to peers.
What did this article say?
Evercore ISI increased its price target for Edwards Lifesciences (EW) to $102 from $100 while keeping an Outperform rating. The upgrade reflects confidence in the company’s earnings outlook and product pipeline. The new target aligns with the average rating of overweight among analysts polled by FactSet. This adjustment signals a modest bullish stance for EW investors.
What did this article say?
Edwards Lifesciences (EW) announced it would host an investor event during the TCT annual scientific symposium on November 2, 2026. The event will feature a live Q&A with physicians and company executives and will be webcast on the firm’s investor relations site. The meeting is intended to provide shareholders with updates on the company’s strategic initiatives and to engage with the medical community. No financial guidance or earnings information was disclosed, and the announcement is routine in nature.
What did this article say?
Edwards Lifesciences received FDA approval for its AUTUS pediatric heart valve, the first expandable device of its kind. The valve is designed to grow with young patients, potentially reducing the need for multiple surgeries. The approval expands EW’s product portfolio into the pediatric segment, adding a new revenue stream. The decision is expected to strengthen the company’s market position and support future growth.
What did this article say?
Edwards Lifesciences (EW) announced that the U.S. Food and Drug Administration approved its AUTUS Size-Adjustable Valve for pediatric pulmonary valve replacement. The approval followed a pivotal study that met primary safety and effectiveness endpoints, with no device-related complications reported through 30 days and no reinterventions through six months. One-year follow-up data showed all patients met valve-performance criteria, and the company plans to continue monitoring patients for ten years. The AUTUS valve had previously received FDA Breakthrough Device designation, underscoring its clinical significance.
What did this article say?
Edwards Lifesciences (EW) received U.S. FDA approval for its AUTUS Size-Adjustable Pulmonary Valve, the first surgical valve specifically designed for pediatric patients with congenital heart disease. The valve can be expanded as a child grows, allowing minimally invasive transcatheter procedures and potentially reducing the need for repeat open‑heart surgeries. This approval positions EW as a pioneer in pediatric valve therapy and expands its product portfolio into a growing market segment.
What did this article say?
Edwards Lifesciences (EW) announced that the U.S. Food and Drug Administration approved its AUTUS Size‑Adjustable Pulmonary Valve, a surgical device tailored for pediatric patients with congenital heart disease. The approval expands EW’s product line into a niche market with limited competition and supports the company’s strategy to broaden its pediatric offerings. The new valve offers adjustable sizing, potentially improving outcomes and reducing re‑intervention rates for young patients.

Technical Analysis

Real-time indicators across multiple timeframes

36
BEARISH
Momentum rank against about 1,000 stocks and ETFs for this timeframe.
Unlock full technicals
Create a free account to access more indicators and deeper timeframe data.
Institutional & Hedge Fund Ownership
25 tracked managers · $23.43B combined position · 13 adding, 12 trimming, 0 unchanged (latest 13F filings)
ManagerTrendShares Held% of Co.Position ValueFiled
Vanguard Group Inc▼ Sell70,079,43512.10%$5.97B2026-01-29
BlackRock, Inc.▲ Buy58,789,43310.15%$5.32B2026-08-07
JPMorgan Chase & Co▲ Buy22,783,1753.93%$2.08B2026-08-12
Wellington Management Group LLP▼ Sell16,827,9672.91%$1.52B2026-08-14
Geode Capital Management, LLC▲ Buy15,437,2512.67%$1.39B2026-08-12
FMR LLC (Fidelity)▼ Sell8,435,9491.46%$763.12M2026-08-13
Norges Bank▼ Sell8,373,7831.45%$757.49M2026-08-12
AllianceBernstein L.P.▲ Buy8,660,4161.50%$693.53M2026-08-14
Bank of America Corp▲ Buy6,692,4241.16%$605.40M2026-08-14
Artisan Partners Limited Partnership▲ Buy6,625,7031.14%$599.36M2026-08-13
Morgan Stanley▼ Sell6,339,3681.09%$573.46M2026-08-13
Northern Trust Corp▼ Sell5,671,2290.98%$513.02M2026-08-13
Goldman Sachs Group Inc▼ Sell4,549,1130.79%$411.51M2026-08-14
Citadel Advisors LLC▲ Buy3,997,9250.69%$361.65M2026-09-02
Invesco Ltd.▼ Sell3,977,5180.69%$359.81M2026-08-14
Millennium Management LLC▲ Buy3,584,7950.62%$324.28M2026-08-14
Neuberger Berman Group LLC▲ Buy2,886,9530.50%$261.24M2026-08-13
Point72 Asset Management, L.P.▼ Sell1,774,1200.31%$160.49M2026-08-14
Two Sigma Investments, LP▲ Buy1,521,8990.26%$137.67M2026-08-14
AQR Capital Management LLC▼ Sell1,465,1850.25%$132.17M2026-08-14
Baillie Gifford & Co▲ Buy1,208,9450.21%$109.36M2026-08-06
Citigroup Inc▲ Buy1,199,3640.21%$108.49M2026-08-03
Wells Fargo & Company▼ Sell1,041,6750.18%$94.23M2026-08-14
Janus Henderson Group plc▲ Buy1,165,6040.20%$93.33M2026-05-18
Man Group plc▼ Sell935,1860.16%$84.60M2026-08-14
Q2 2026 flow:26.42M sh bought ($2.34B)15.36M sh sold ($1.39B)net +11.06M sh (+$946.80M)
Congressional Trading Activity
9 disclosed trades · ~$163.5K est. traded value · 5 buys, 4 sells
MemberChamberStateTypeAmountTradedFiled
Alan ArmstrongSenateOK▲ Buy$1K - $15K2026-03-272026-07-21
Josh GottheimerHouseNJ05▼ Sell$1K - $15K2025-11-192025-12-29
Jefferson ShreveHouseIN06▼ Sell$50K - $100K2025-05-122025-06-22
Bruce WestermanHouseAR04▼ Sell$1K - $15K2025-04-212025-05-12
Rob BresnahanHousePA08▲ Buy$1K - $15K2025-04-082025-05-08
Jefferson ShreveHouseIN06▲ Buy$15K - $50K2025-04-072025-05-08
Bruce WestermanHouseAR04▲ Buy$1K - $15K2025-03-032025-04-16
Tommy TubervilleSenateAL▼ Sell$1K - $15K2023-04-032023-05-12
Tommy TubervilleSenateAL▲ Buy$1K - $15K2021-03-292021-07-23